UCB-35440

• Description :

  UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation[1][2].

• CAS Number :

  [299460-62-1]

• UNSPSC :

  12352005

• Target :

  Histamine Receptor; Lipoxygenase

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/ucb-35440.html

• Purity :

  99.38

• Solubility :

  DMSO : 20 mg/mL (ultrasonic)

• Smiles :

  O=C(N)C1=CC(C#CCCN(C(N)=O)O)=CC=C1OCCN2CCN([C@@H](C3=CC=C(Cl)C=C3)C4=CC=CC=C4)CC2

• Molecular Formula :

  C31H34ClN5O4

• Molecular Weight :

  576.09

• References & Citations :

  [1]Giannaras A, et al. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol. 2005 Jan 4;506 (3) :265-71. |[2]Oliver Werz, et al. Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds. Expert Opin Ther Patents. 2005 May 10; 15 (5) :505-519.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2